Literature DB >> 20714812

An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases.

Eduardo Maldonado-Gonzales1, Peter Pietschmann.   

Abstract

Over the years, the importance of receptor activator of nuclear factor κB ligand (RANKL) in bone physiology and pathophysiology has been thoroughly documented. Denosumab, also known as AMG 162, is a fully human monoclonal antibody against RANKL which is being studied in the treatment of metabolic, inflammatory, and malignant bone diseases. The purpose of this review is to analyze the potential role of denosumab in osteoporosis, rheumatoid arthritis, bone metastases and multiple myeloma.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20714812     DOI： 10.1007/s10354-010-0812-3

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN： 0043-5341


  43 in total

Review 1.  Osteoclast differentiation and activation.

Authors:  William J Boyle; W Scott Simonet; David L Lacey
Journal:  Nature       Date:  2003-05-15       Impact factor: 49.962

2.  The effect of a single dose of osteoprotegerin in postmenopausal women.

Authors:  P J Bekker; D Holloway; A Nakanishi; M Arrighi; P T Leese; C R Dunstan
Journal:  J Bone Miner Res       Date:  2001-02       Impact factor: 6.741

3.  Breast cancer cells interact with osteoblasts to support osteoclast formation.

Authors:  R J Thomas; T A Guise; J J Yin; J Elliott; N J Horwood; T J Martin; M T Gillespie
Journal:  Endocrinology       Date:  1999-10       Impact factor: 4.736

4.  Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates.

Authors:  Karim Fizazi; Allan Lipton; Xavier Mariette; Jean-Jacques Body; Yasmin Rahim; Julie R Gralow; Guozhi Gao; Ling Wu; Winnie Sohn; Susie Jun
Journal:  J Clin Oncol       Date:  2009-02-23       Impact factor: 44.544

5.  Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.

Authors:  Jacques P Brown; Richard L Prince; Chad Deal; Robert R Recker; Douglas P Kiel; Luiz H de Gregorio; Peyman Hadji; Lorenz C Hofbauer; Jose M Alvaro-Gracia; Huei Wang; Matthew Austin; Rachel B Wagman; Richard Newmark; Cesar Libanati; Javier San Martin; Henry G Bone
Journal:  J Bone Miner Res       Date:  2009-01       Impact factor: 6.741

6.  Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial.

Authors:  Paul D Miller; Michael A Bolognese; E Michael Lewiecki; Michael R McClung; Beiying Ding; Matthew Austin; Yu Liu; Javier San Martin
Journal:  Bone       Date:  2008-04-26       Impact factor: 4.398

7.  A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.

Authors:  Jean-Jacques Body; Philip Greipp; Robert E Coleman; Thierry Facon; Filip Geurs; Jean-Paul Fermand; Jean-Luc Harousseau; Allan Lipton; Xavier Mariette; Catherine D Williams; Arline Nakanishi; Donna Holloway; Steven W Martin; Colin R Dunstan; Pirow J Bekker
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

8.  Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma.

Authors:  Karin Vanderkerken; Evy De Leenheer; Claire Shipman; Kewal Asosingh; Angelo Willems; Ben Van Camp; Peter Croucher
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

9.  Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates.

Authors:  Robin K Dore; Stanley B Cohen; Nancy E Lane; William Palmer; William Shergy; Lifen Zhou; Huei Wang; Wayne Tsuji; Richard Newmark
Journal:  Ann Rheum Dis       Date:  2009-09-03       Impact factor: 19.103

10.  Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer.

Authors:  Georgiana K Ellis; Henry G Bone; Rowan Chlebowski; Devchand Paul; Silvana Spadafora; Judy Smith; Michelle Fan; Susie Jun
Journal:  J Clin Oncol       Date:  2008-08-25       Impact factor: 44.544
View more
  4 in total

Review 1.  [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].

Authors:  Stefan Kudlacek; Thomas Puntus
Journal:  Wien Med Wochenschr       Date:  2012-08-09

Review 2.  RANKL/RANK-beyond bones.

Authors:  Reiko Hanada; Toshikatsu Hanada; Verena Sigl; Daniel Schramek; Josef M Penninger
Journal:  J Mol Med (Berl)       Date:  2011-03-29       Impact factor: 4.599

Review 3.  Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.

Authors:  Colin Thorbinson; Louise Oni; Eve Smith; Angela Midgley; Michael W Beresford
Journal:  Paediatr Drugs       Date:  2016-06       Impact factor: 3.022

Review 4.  Immunology of Osteoporosis: A Mini-Review.

Authors:  Peter Pietschmann; Diana Mechtcheriakova; Anastasia Meshcheryakova; Ursula Föger-Samwald; Isabella Ellinger
Journal:  Gerontology       Date:  2015-06-17       Impact factor: 5.140
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.